Drugs / Autologous genetically modified ADP-A2M4CD8 cells
Autologous genetically modified ADP-A2M4CD8 cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05601752 | Jun 2023 → Aug 2026 overdue | ovarian cancer | USWM CT, LLC | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous genetically modified ADP-A2M4CD8 cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05601752 ↗ |
| Modality | Cell therapy | “Genetic: Autologous genetically modified ADP-A2M4CD8 cells” NCT05601752 ↗ |